11 Best Genomics Stocks to Buy According to Hedge Funds

6. Exact Sciences Corporation (NASDAQ:EXAS)

Number of Hedge Fund Holders: 41

Exact Sciences Corporation (NASDAQ:EXAS) has released fresh data from the Beta-CORRECT study that validates the clinical efficacy of its tumor-informed Oncodetect™ test for recurrence monitoring in stage II-IV colorectal cancer.

The findings, presented at ASCO 2025, revealed that patients with ctDNA-positive results after therapy and during surveillance had a 24- and 37-fold greater risk of recurrence, respectively. The business also disclosed plans to introduce a next-generation test in 2026 that will use Broad Institute’s MAESTRO technology, which can track up to 5,000 patient-specific variations and identify ctDNA levels below 1 part per million.

Oncodetect, which was created for molecular residual disease identification, has improved prognosis prediction over standard-of-care approaches in stage III colorectal cancer, as proven by both Alpha- and Beta-CORRECT trials.

The revised version uses whole-genome sequencing that is solely licensed from the Broad Institute to improve sensitivity and scalability. This is Exact Sciences Corporation (NASDAQ:EXAS)’s largest MRD clinical research to date, with over 400 patients enrolled, and it reflects the company’s ambition to enhance precision oncology through advances based on ctDNA. It is ranked sixth on our list of the Best Genomics Stocks.